10-Q: Ensysce Biosciences Reports Increased Grant Revenue but Continues to Face Going Concern Challenges in Q1 2025

Ensysce Biosciences' Q1 2025 shows increased grant revenue and reduced net loss compared to Q1 2024, but the company still faces substantial doubt about its ability to continue as a going concern.

Summary

• Ensysce Biosciences reported a net loss of $1.946 million for the three months ended March 31, 2025, compared to a net loss of $3.117 million for the same period in 2024.
• The company's federal grant revenue increased to $1.320 million in Q1 2025 from $0.306 million in Q1 2024, driven by increased activities under the MPAR grant.
• Research and development expenses increased to $1.886 million in Q1 2025 from $0.779 million in Q1 2024, primarily due to external costs related to clinical and pre-clinical programs for PF614-MPAR.
• General and administrative expenses remained relatively stable at $1.402 million in Q1 2025 compared to $1.370 million in Q1 2024.
• As of March 31, 2025, Ensysce had $3.052 million in cash and cash equivalents.
• The company believes its current cash on hand is sufficient to fund operations into the third quarter of 2025.
• Ensysce's ability to continue as a going concern is dependent on its ability to obtain adequate financing and achieve profitable operations.
• The company completed a registered direct offering in March 2025, raising approximately $1.1 million before deductions.
• The company has commitments of approximately $8.1 million related to open purchase orders and contractual obligations as of March 31, 2025.
• The company entered into a product development and supply agreement with Galephar Pharmaceutical Research, Inc. in January 2025 to support the development, manufacture, packaging and testing of the company's PF614 and PF614-MPAR drug products.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company shows improvements in grant revenue and reduced net loss, the going concern warning and need for additional financing raise concerns. The company's progress in clinical trials and focus on addressing the opioid crisis are positive aspects, but the financial challenges outweigh these factors.

Positives

• Federal grant revenue increased significantly, indicating successful grant applications and ongoing research funding.
• Net loss decreased, suggesting improved cost management or increased revenue generation.
• The company successfully completed a registered direct offering, providing additional capital.
• The company has a new multi-year MPAR Grant providing total funding of $ 14 million through May 2027.

Negatives

• The company continues to experience net losses, indicating that it is not yet profitable.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• The company's cash on hand is only sufficient to fund operations into the third quarter of 2025, requiring additional financing.
• Research and development expenses increased, indicating higher spending on drug development without immediate revenue generation.

Risks

• The company's ability to continue as a going concern is dependent on its ability to obtain adequate financing.
• The company's product candidates may not be successful in clinical trials or receive regulatory approval.
• The company may be unable to successfully market or gain market acceptance of its product candidates.
• The company faces competition from other pharmaceutical companies.
• The company is dependent on third parties for laboratory, clinical development, manufacturing, and other critical services.
• The company may be unable to obtain and maintain sufficient intellectual property protection for its investigational products.
• The company may lose key members of its management team.
• The company's common stock could be delisted from Nasdaq.

Future Outlook

The company expects to incur substantial expenses in the foreseeable future for the development and potential commercialization of its product candidates and ongoing internal research and development programs. The company believes that current cash on hand is sufficient to fund operations into the third quarter of 2025. The company's future viability beyond the twelve months is dependent on its ability to raise additional capital to finance its operations.

Management Comments

• Management believes that the information provided in the report is relevant to an assessment and understanding of the company's consolidated results of operations and financial condition.
• Management has concluded that the company's financial statements included in the Quarterly Report on Form 10-Q are fairly stated in all material respects in accordance with GAAP for each of the periods presented therein.

Industry Context

Ensysce Biosciences operates in the competitive pharmaceutical and biotechnology industry, focusing on developing innovative solutions for pain management and overdose prevention. The company's focus on abuse-deterrent and overdose-resistant opioid formulations addresses a critical need in the market, given the ongoing opioid crisis. However, the company faces competition from other pharmaceutical companies developing similar products, as well as challenges related to regulatory approvals, clinical trial outcomes, and market acceptance.

Comparison to Industry Standards

• It is difficult to compare Ensysce's results directly to industry standards due to its clinical-stage nature and lack of commercial products.
• Comparable companies in the clinical-stage biotech sector often have high R&D expenses and net losses as they invest heavily in drug development.
• The company's reliance on federal grants for funding is common among early-stage biotech companies, but it also highlights the need for additional capital to advance its pipeline.
• The company's focus on abuse-deterrent formulations aligns with industry trends and regulatory efforts to combat the opioid crisis.
• Companies like Alkermes and Collegium Pharmaceutical also focus on abuse-deterrent opioid formulations, but they have commercial products and established revenue streams, setting them apart from Ensysce.

Legal Proceedings

• In April 2025, the Company entered into an agreement with a former independent contractor to resolve a dispute over payment.

Related Party Transactions

• As of March 31, 2025, the company held a $0.2 million senior secured convertible promissory note plus accrued interest and 29,547 warrants exercisable for common stock at $23.51 per share issued to a board member in connection to the issuance of the 2023 Notes.
• The company and the board member have entered into a forbearance agreement that will expire on April 25, 2026.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings.
• Employees face uncertainty due to the company's going concern challenges.
• Patients may benefit from the company's development of abuse-deterrent and overdose-resistant opioid formulations.
• Suppliers and creditors face the risk of non-payment if the company is unable to secure additional financing.

Next Steps

• The company plans to continue preclinical studies and existing clinical trials for PF614, PF614-MPAR and nafamostat.
• The company plans to advance the development of its product candidate pipeline of other product candidates.
• The company plans to maintain, expand and protect its intellectual property portfolio.
• The company plans to seek regulatory approval for any product candidates that successfully complete clinical trials.
• The company plans to undertake any pre-commercialization activities to establish sales, marketing and distribution capabilities for any product candidates for which it may receive regulatory approval.

Key Dates

Keywords

Ensysce Biosciences, PF614, PF614-MPAR, TAAP, MPAR, Opioid Use Disorder, Clinical Trials, Registered Direct Offering, Federal Grants, Going Concern, Pharmaceutical, Biotech